申请人:MOCHIDA PHARMACEUTICAL CO., LTD.
公开号:EP0773219A1
公开(公告)日:1997-05-14
Specified imidazoquinoline derivatives represented by the formula (I):
[where Q represents an optionally substituted phenyl, pyridyl or furyl group; Y represents either a hydrogen atom or, when taken together with Z, an oxygen atom, a methylene group or the following formula (II):
=N-OR1 (II)
Z represents a hydrogen atom, a hydroxymethyl group, a carboxymethyl group, a 2-oxo-1-pyrrolidinyl group or the following formula (III):
-A-R2 (III)
(where A represents an oxygen atom, a sulfur atom or the group -NH-)] or salts of such derivatives inhibit the increase of eosinophils and are useful as agents for preventing and/or treating diseases that manifest the increase of eosinophils.
由式(I)代表的特定咪唑喹啉衍生物:
[其中 Q 代表任选取代的苯基、吡啶基或呋喃基;Y 代表氢原子或与 Z 合在一起时代表氧原子、亚甲基或下式(II):
=N-OR1 (II)
Z 代表氢原子、羟甲基、羧甲基、2-氧代-1-吡咯烷基或下式 (III):
-A-R2 (III)
(其中 A 代表氧原子、硫原子或基团 -NH-)]或此类衍生物的盐可抑制嗜酸性粒细胞的增加,可用作预防和/或治疗表现为嗜酸性粒细胞增加的疾病的药物。